Pharmacological investigations of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370). 1. Anti-inflammatory, analgesic and antipyretic properties.
D000284:Administration, Oral; D000700:Analgesics / Q000008:administration & dosage* / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002351:Carrageenan; D004487:Edema / Q000188:drug therapy; D004890:Erythema / Q000188:drug therapy; D005260:Female; D005334:Fever / Q000188:drug therapy; D006099:Granuloma / Q000188:drug therapy; D006168:Guinea Pigs; D006941:Hyperesthesia / Q000188:drug therapy; D007275:Injections, Intravenous; D007616:Kaolin; D008297:Male; D051379:Mice; D010538:Peritonitis / Q000188:drug therapy; D010653:Phenylbutazone / Q000008:administration & dosage / Q000627:therapeutic use; D011720:Pyrazoles / Q000008:administration & dosage* / Q000627:therapeutic use; D051381:Rats; D013729:Terpenes / Q000008:administration & dosage* / Q000627:therapeutic use; D014466:Ultraviolet Rays
D000700:Analgesics; D000893:Anti-Inflammatory Agents; D011720:Pyrazoles; D013729:Terpenes; D007616:Kaolin; D002351:Carrageenan; D010653:Phenylbutazone